Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 62.16 USD -1.88%
Market Cap: 7.6B USD

EV/EBIT
Enterprise Value to EBIT

-13.4
Current
-9.6
Median
7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-13.4
=
Enterprise Value
7.7B USD
/
EBIT
-572.9m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
Cytokinetics Inc
NASDAQ:CYTK
Average EV/EBIT: 45.1
Negative Multiple: -13.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
59.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-12.3
2-Years Forward
EV/EBIT
-11.4
3-Years Forward
EV/EBIT
-17.5